- Email: [email protected]
5071961 Method of enrichment of coagulation factors II, VII, IX and X
PATENT
ABSI-RACTS
317
5071867
5071962
TREATMENT OF CHRONIC KIDNEY DISEASE WITH ANGIOTENSIN I CONVERTING ENZYME INHIBITOR
NUCLEOTIDE, DEDUCED AMINO ACID SEQUENCE, ISOLATION AND PURIFICATION OF HEATSHOCK CHLAMYDIAL PROTEINS
Iekuni Ichikawa, Agnes Fogo, Masaaki Ikoma, Tetsuy Kawamura assigned to Vanderbilt University
Richard P Morrison, Harlan D Caldwell assigned to The United State of America as represented by the Department of Health and Human Services
A method of healing extracellular matrix degradation to reverse glomerular sclerosis includes the steps of administering on angiotension I converting enzyme inhibitor and suppressing extracellular matrix release independent of the blood pressure effects of the enzyme inhibitor.
5071957 ANTIBIOTIC
BU-4061T
Masataka Konishi, Minoru Hanada, Yuji Nishiyama, Kawasaki, Japan assigned to Bristol-Myers Company The antibiotic designated BU-4061T is produced by fermentation of actinomycete strain 4996-17 (ATCC-53904). The BU-4061T antibiotic exhibits both in vitro and in vivo antitumor activity.
The present invention relates to novel polypeptides comprising a unique chlamydialspecific primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokaryotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.
5071961 METHOD OF ENRICHMENT OF COAGULATION FACTORS II, VII, IX AND X Michae Kraus, Wolfgang Moller, Bertram Eichentopf, Frankfurt, Federal Republic Of Germany assigned to Biotest Pharma GmbH A method of enrichment of coagulation Factors II, VII, IX and X in preparations obtained from plasma, plasma fractions, or other liquids containing the factors, by adsorbing the factor or factors onto a polymeric matrix that carries an alpha-hydroxylamine group, and eluting the factors. When the chromatography conditions are appropriate, it is also easy to prepare a highly concentrated Factor IX preparation with a purity of more than 10 U per mg of protein.
5071963 INTERFERON-INDUCED HUMAN (2’4’) OLIGO A SYNTHETASE Michel Revel, Judit Chebath, Rehovot, Israel assigned to Yeda Research and Developement Co Ltd Human DNA encoding enzymes having (2-5’) oligo A synthetase has been sequenced. The amino acid sequences of the enzymes have been deduced. Antigenic peptides have been prepared and have been used to raise antibodies which recognize and immunoprecipitate the 40 kd, 46 kd, 67 kd and 100 kd forms of (2’-5’) oligo A syntheta% Methods of monitoring interferon activity in a subject are presented.
ABSI-RACTS
317
5071867
5071962
TREATMENT OF CHRONIC KIDNEY DISEASE WITH ANGIOTENSIN I CONVERTING ENZYME INHIBITOR
NUCLEOTIDE, DEDUCED AMINO ACID SEQUENCE, ISOLATION AND PURIFICATION OF HEATSHOCK CHLAMYDIAL PROTEINS
Iekuni Ichikawa, Agnes Fogo, Masaaki Ikoma, Tetsuy Kawamura assigned to Vanderbilt University
Richard P Morrison, Harlan D Caldwell assigned to The United State of America as represented by the Department of Health and Human Services
A method of healing extracellular matrix degradation to reverse glomerular sclerosis includes the steps of administering on angiotension I converting enzyme inhibitor and suppressing extracellular matrix release independent of the blood pressure effects of the enzyme inhibitor.
5071957 ANTIBIOTIC
BU-4061T
Masataka Konishi, Minoru Hanada, Yuji Nishiyama, Kawasaki, Japan assigned to Bristol-Myers Company The antibiotic designated BU-4061T is produced by fermentation of actinomycete strain 4996-17 (ATCC-53904). The BU-4061T antibiotic exhibits both in vitro and in vivo antitumor activity.
The present invention relates to novel polypeptides comprising a unique chlamydialspecific primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokaryotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.
5071961 METHOD OF ENRICHMENT OF COAGULATION FACTORS II, VII, IX AND X Michae Kraus, Wolfgang Moller, Bertram Eichentopf, Frankfurt, Federal Republic Of Germany assigned to Biotest Pharma GmbH A method of enrichment of coagulation Factors II, VII, IX and X in preparations obtained from plasma, plasma fractions, or other liquids containing the factors, by adsorbing the factor or factors onto a polymeric matrix that carries an alpha-hydroxylamine group, and eluting the factors. When the chromatography conditions are appropriate, it is also easy to prepare a highly concentrated Factor IX preparation with a purity of more than 10 U per mg of protein.
5071963 INTERFERON-INDUCED HUMAN (2’4’) OLIGO A SYNTHETASE Michel Revel, Judit Chebath, Rehovot, Israel assigned to Yeda Research and Developement Co Ltd Human DNA encoding enzymes having (2-5’) oligo A synthetase has been sequenced. The amino acid sequences of the enzymes have been deduced. Antigenic peptides have been prepared and have been used to raise antibodies which recognize and immunoprecipitate the 40 kd, 46 kd, 67 kd and 100 kd forms of (2’-5’) oligo A syntheta% Methods of monitoring interferon activity in a subject are presented.